The Drug-Induced Respiratory Disease Website
Philippe Camus, M.D.
Browse by »
Antiplatelet (-P2Y) agents
Dyspnea, unexplained otherwise
Last update :
Drug and radiation history
Drug singularity - Correct identification of the drug
Consistent timing of exposure v. onset of symptoms
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
Careful exlusion of another cause
Remission of symptoms with removal of drug
Recurrence with rechallenge (rarely advisable)
More detailed checklist
See also under
Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics.
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel.